FDA 483 OBSERVATION · #835 OF 1,932 MOST-CITED

When to report

FDA cited this observation 23 times across 22 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics23
BY FISCAL YEAR
FY20261
FY20243
FY20232
FY20221
FY20192
FY20187
FY20173
FY20164

How FDA worded it — real examples

Biological product deviations not reported within the 45 calendar day timeframe.

Bavarian Nordic A/S · Kvistgard · Biologics · 2025-12-09

Biological product deviations were not reported within the 45 calendar day timeframe.

Ochsner Health System Blood Bank · New Orleans, Louisiana · Biologics · 2024-07-05

Biological product deviations not reported within the 45 calendar day timeframe.

Allermed Laboratories, Inc. · San Diego, California · Biologics · 2024-01-31

Biological product deviations are not reported within the 45 calendar day timeframe.

Novartis Innovative Technologies Inc. · Durham, North Carolina · Biologics · 2024-01-26

Biological product deviations were not reported within the 45 calendar day timeframe.

New York Blood Center Enterprises · Rye, New York · Biologics · 2023-07-06

Biological product deviations were not reported within the 45 calendar day timeframe.

Ortho-Clinical Diagnostics, Inc. · Raritan, New Jersey · Biologics · 2022-12-09

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →